



Review

# Targeting Epigenetic Regulators with HDAC and BET Inhibitors to Modulate Muscle Wasting

Lorenzo Nevi <sup>1</sup>, Noora Pöllänen <sup>2</sup>, Fabio Penna <sup>3</sup> and Giuseppina Caretti <sup>1,\*</sup>

<sup>1</sup> Department of Biosciences, University of Milan, 20133 Milan, Italy; nevi.lorenzo@hsr.it

<sup>2</sup> Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland

<sup>3</sup> Department of Clinical and Biological Sciences, University of Torino, 10125 Torino, Italy

\* Correspondence: giuseppina.caretti@unimi.it

**Abstract:** Epigenetic changes contribute to the profound alteration in the transcriptional program associated with the onset and progression of muscle wasting in several pathological conditions. Although HDACs and their inhibitors have been extensively studied in the field of muscular dystrophies, the potential of epigenetic inhibitors has only been marginally explored in other disorders associated with muscle atrophy, such as in cancer cachexia and sarcopenia. BET inhibitors represent a novel class of recently developed epigenetic drugs that display beneficial effects in a variety of diseases beyond malignancies. Based on the preliminary *in vitro* and preclinical data, HDACs and BET proteins contribute to the pathogenesis of cancer cachexia and sarcopenia, modulating processes related to skeletal muscle mass maintenance and/or metabolism. Thus, epigenetic drugs targeting HDACs and BET proteins may emerge as promising strategies to reverse the catabolic phenotype associated with cachexia and sarcopenia. Further preclinical studies are warranted to delve deeper into the molecular mechanisms associated with the functions of HDACs and BET proteins in muscle atrophy and to establish whether their epigenetic inhibitors represent a prospective therapeutic avenue to alleviate muscle wasting.

**Keywords:** epigenetics; muscle wasting; cachexia; sarcopenia; BET proteins; HDACs



**Citation:** Nevi, L.; Pöllänen, N.; Penna, F.; Caretti, G. Targeting Epigenetic Regulators with HDAC and BET Inhibitors to Modulate Muscle Wasting. *Int. J. Mol. Sci.* **2023**, *24*, 16404. <https://doi.org/10.3390/ijms242216404>

Academic Editor: Daniel Taillandier

Received: 13 October 2023

Revised: 7 November 2023

Accepted: 13 November 2023

Published: 16 November 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Muscle wasting occurs in different conditions and entails the progressive loss of skeletal muscle and function; this leads to loss of independence and negative effects on an individual's quality of life. Muscle loss can be induced by multiple causes such as immobility [1], malnutrition/starvation [2], pharmacological treatment [3], or a wide range of diseases involving the muscle tissue, for instance in cachexia secondary to cancer, renal failure, and chronic obstructive pulmonary diseases [4,5]. Likewise, aging is accompanied by a progressive decline in muscle mass, quality, and strength, which can become a pathological state known as sarcopenia that affects more than half of individuals aged >80 years [6]. In addition, loss of muscle mass and function develops in patients affected by genetic muscular dystrophies, such as Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) [7].

Although the onset and the underlying molecular mechanisms driving muscle wasting differ in such pathological states, muscle loss consistently represents a negative prognostic factor for the progression of the disorder [4].

Epigenetic factors influence chromatin structure and gene expression in all tissues throughout life and undergo many key modifications during disease onset and aging. Several chromatin factors have been described to interplay with transcription factors to modify the epigenetic landscape at specific loci in muscle diseases. In addition, since epigenetic changes are reversible and can be modified by pharmacological intervention, epigenetic drugs may become a pivotal tool to temper the progression of muscle atrophy. Among

the multiple classes of epigenetic inhibitors currently on the market, histone deacetylase (HDAC) inhibitors have received the broadest attention because of their employment in the clinics as a pharmacological avenue for cancer treatment [8,9].

HDAC inhibitors have been extensively studied in muscle dystrophy mouse models, [10] and the givinostat molecule was approved in 2023 for Duchenne muscular dystrophy [9,11,12]. HDAC's role in skeletal muscle and in the mononucleated cells within the muscle tissue, as well as the impact of HDAC inhibitors in muscular dystrophies, has been recently accurately reviewed by Sandon et al. [13] and will not be discussed in this review.


More recently, a novel class of epigenetic inhibitors has been rapidly developed targeting the bromodomain and extraterminal domain (BET) family of proteins, and the first efforts have been made to test their impact on skeletal muscle wasting [14–16].

In this review, we will focus our attention on the molecular mechanisms involving HDACs and BET proteins in sarcopenia and cancer cachexia and how epigenetic modulators targeting these two classes of epigenetic factors may contribute to alleviating muscle wasting in the abovementioned pathologies.

## 2. Signaling Pathways Involved in Sarcopenia and Cachexia

Chromatin factors can contribute to muscle wasting in two ways: (i) by directly modulating histone modifications at regulatory regions relevant for transcriptional regulation of pro-atrophy and metabolic genes or (ii) by modulating the activity of transcription factors and co-activators through their post-translational modifications (Figures 1 and 2). To provide a few examples, we will first describe the signaling pathways that drive muscle wasting in sarcopenia and cachexia. Then, we will define how HDAC and BET epigenetic factors and their pharmacological modulators impact muscle wasting.


Sarcopenia is a complex condition and its onset and progression have been proposed to depend on multiple factors, such as changes in hormones, immobility, age-related muscle changes, nutrition, neuromuscular factors, oxidative stress, and inflammation [17]. Furthermore, these factors often interact with one another, making the development and progression of sarcopenia a multifaceted process. At the intracellular level, these factors affect key processes in skeletal muscle, such as proteostasis, mitochondria homeostasis and muscle regeneration.



**Figure 1.** HDAC and BET proteins may contribute to muscle wasting through chromatin and non-histone protein modifications. (a) Transcription is regulated by the interplay between the HAT writer and HDAC erasers. Histone acetylation promotes transcription through the association of several different proteins and complexes, including the BET readers. (b) Transcription factors and co-activators are HATs and HDACs substrates. The association of the acetylated form of Foxo3 and NF-κB with BRD4 has been described in other contexts [18,19] and may play a role in skeletal muscle also.

Cancer-associated cachexia is a complex metabolic syndrome that accompanies various malignancies and is associated with increased morbidity and mortality. Muscle wasting in cachexia is mainly caused by the loss of proteostasis, implying impaired protein synthesis and increased proteolysis, and is primarily driven by the ubiquitin–proteasome system (UPS), autophagy, and the calpain pathway. The primary mediators of cancer cachexia are inflammatory signals, the TGF $\beta$  family members myostatin and activin A, hormones, and a reduction in anabolic signals.

Thus, cachexia and sarcopenia share an unbalanced equilibrium between protein degradation and protein synthesis; however, these events are characterized by distinct underlying molecular mechanisms and causes in the two pathologies. Although there are similarities in some of the molecular mechanisms involved in both cachexia and sarcopenia (e.g., inflammation and altered muscle proteostasis), the primary drivers and the severity of these mechanisms differ between the two conditions [4].



**Figure 2.** The signaling pathways contributing to cancer cachexia and sarcopenia are highlighted, focusing on downstream nuclear targets and the transcriptional programs affected by extracellular factors that lead to muscle wasting. The grey boxes depict the intracellular processes primarily involved in sarcopenia and cachexia, whereas the dark grey hexagons represent epigenetic drugs affecting the underlying molecular processes. Ac represents acetylated lysine residues. Image created with PowerPoint and Smart Servier.

### 2.1. Inflammatory Signaling Pathways

Pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF- $\alpha$ ), interleukin 6 (IL-6), and interleukin 1 (IL-1) are considered as the primary mediators of cancer-associated cachexia, since the multiple inflammatory cytokines originating from the tumor or stromal cells contribute to the activation of muscle proteolysis [5]. Low-grade chronic inflammation, often referred to as “inflammaging”, also plays a role in sarcopenia, although its impact is less severe than the inflammation seen in cachexia [20]. In chronic inflammation, IL-6 secretion leads to the generation of a damaging environment for the muscle cells. In fact, a strong association between high IL-6 levels and loss of body mass has been observed in the elderly [21]. An observational study with more than 2000 elderly people revealed that higher TNF- $\alpha$  levels were associated with decreased muscle mass and strength [22]. In addition, during aging, senescent cells express the senescence-associated secretory phenotype (SASP) as a paracrine signaling pathway. “Inflammaging” and SASP production in senescent skeletal muscle cells converge on the activation of nuclear factor kappa B (NF- $\kappa$ B) signaling (Figure 2).

## 2.2. Protein Degradation

The two main protein degradation systems, the ubiquitin–proteasome system and autophagy, are highly activated in cachexia [23–25], causing loss of muscle mass and strength. Pro-inflammatory cytokines induce the activation of the signal transducer of activation of transcription 3 (STAT3), NF- $\kappa$ B, and forkhead box 1/3 (FoxO1/3) transcription factors, which promote the transcription of the muscle-specific E3 ubiquitin ligases Atrogin 1 and MuRF1 and other atrogenes, which promote UPS activation [26–28] (Figure 2).

Although the initial reports suggested an increase in muscle proteasome activity with aging in rats, these data do not incorporate the robust activation program of the atrogenes that is typically associated with the rapid muscle atrophy observed in cachexia [29]. The role of MuRF1 and Atrogin 1 in sarcopenia has been controversial: certain reports show a modest increase in the expression of these E3 ubiquitin ligases with aging in the mouse TA [30], others show no change in humans [31], and others a reduction in rats [32]. The inconsistent role of muscle-specific E3 ubiquitin ligases has been further supported by the finding that the proteolytic systems do not significantly increase in the elderly and in mouse models [33].

Autophagy also increases in cachexia, where the transcription factors FoxO1/3 activate autophagy-related genes such as *M P1LC3a* and BNIP3, encoding for the LC3 and BNIP3 proteins respectively [25].

Conversely, in sarcopenic muscles, a defective formation of the autophagosome and an impairment of the autophagic flux has been observed. This is probably due to a downregulation of the LC3 gene and protein expression pattern (LC3 is involved in the autophagosome formation) and LAMP-2 (a crucial protein that mediates fusion of the autophagosome with the lysosome) [34,35]. Consequently, sarcopenia is characterized by an insufficient clearance of intracellular waste material and to the accumulation of protein aggregates and damaged mitochondria that are not removed, eventually leading to the blockade of protein synthesis, thus causing muscle loss. Indeed, dysregulated elimination of mitochondria through mitophagy has been suggested as a driver of sarcopenia [36].


## 2.3. Protein Synthesis and the IGF1/ KT/mTOR Pathway

The anabolic growth factor insulin-like growth factor 1 (IGF1), Akt, and mammalian target of rapamycin (mTOR) signaling pathways play a central role in modulating skeletal muscle protein turnover in physiological and pathological conditions [25,33]. During the catabolic state observed in cachexia, the reduced activation of the IGF1/AKT pathway results in reduced AKT-dependent FoxO inhibition and in the activation of pro-atrophic transcriptional programs that are under the control of FoxO1/3 (Figure 2). Several in vivo and in vitro studies [25,26,37,38] have demonstrated that FoxO1 and FoxO3 play a primary role in muscle atrophy, actively promoting the expression of E3 ubiquitin ligases and of autophagy genes in cancer cachexia. Likewise, in the aging muscle, protein synthesis is defective. In humans, rats and mice, sarcopenia is characterized by the reduced sensitivity of muscle protein synthesis to the anabolic signals triggered by amino acids, insulin, and various nutrients and hormones associated with protein metabolism after food intake [33,39–42]. Several atrophy-related genes are under the control of transcription factors such as FoxO3 and NF- $\kappa$ B [33] and various post-translational modifications control FoxO1 and FoxO3 activity, including activation through phosphorylation by MST1 or AMPK [43] and inactivation through phosphorylation by Akt [33], deacetylation by sirtuin 1 (Sirt1) [44], or by binding with the oncogene JUNB or the PPAR $\gamma$  coactivator 1 alpha PGC-1 [4].

## 2.4. Mitochondrial abnormalities and the Sirt1/PGC-1 Pathway

Aging is characterized by mitochondrial dysfunction in the muscles of both humans and rodents. This dysfunction includes impaired oxidative phosphorylation, reduced mitochondrial DNA content and accumulation of mutated mitochondria DNA, dysfunctional fission/fusion, and impaired mitophagy [45–48]. The AMPK–SIRT1–PGC-1 signaling pathway plays a critical role in sensing energy levels and subsequently regulating mito-

chondrial production, energy metabolism, and managing oxidative stress [49]. AMPK orchestrates the transition between anabolic and catabolic metabolism [50]. In muscle, this transition is achieved through the AMPK-dependent activation of an additional metabolic sensor, SIRT1, which leads to the deacetylation of downstream targets such as PGC-1 [51] (Figure 3b). Thus, whereas in the healthy muscle the AMPK–SIRT1–PGC-1 axis plays a pivotal role in regulating mitochondrial biosynthesis and homeostasis, in the aging mouse muscle, PGC-1 acetylation was reported to increase compared with the young muscle, hinting at a much reduced ability to transactivate its target genes [52] (Figure 2).



**Figure 3.** HDAC and BET family member classification and domain composition. **(a)** HDAC family: on the left, we indicate in light orange the conserved deacetylase domain of the classical HDACs and in blue the catalytic domain of the sirtuins. The solid blue color indicates deacetylase activity and the striped pattern indicates domains in which the deacetylase activity remains elusive or is associated with other catalytic activities. We reported in light yellow myocyte-specific enhancer factor 2A (MEF2)-binding site, the S symbol indicates the key serine residues that are phosphorylated, in green are the leucine-rich regions, and in dark pink we indicate C-terminal zinc finger (ZnF). **(b)** BET family members: on the right, we indicate in yellow the two bromodomains, in pink the extra-terminal domain (ET), and in light blue the C-terminal domain (CTD).

A recent study focused on the transcription profile of muscles of sarcopenic individuals and age-matched controls revealed that individuals with sarcopenia consistently exhibited significant changes in the expression of genes related to mitochondrial bioenergetic dysfunctions. These changes included a reduction in the signature genes regulated by PGC-1 and downregulation of genes associated with oxidative phosphorylation and mitochondrial proteostasis. Functionally, these transcriptional changes resulted in fewer mitochondria, reduced expression and activity of mitochondrial respiratory complexes, and low levels of NAD<sup>+</sup> in sarcopenic muscles [53]. Furthermore, it has been shown that the decreased bioenergetic availability in skeletal muscle is associated with a reduction in the number of mitochondria and their functionality [54].

In experimental models of cancer cachexia, muscle is characterized by imbalanced mitochondrial dynamics (increased fission and reduced fusion), decreased activity of respiratory chain complexes, and mitophagy [55,56].

A genome-wide analysis of a cancer-induced cachexia mouse model revealed reduced expression of the genes related to mitochondrial fusion, fission, ATP production, and mitochondrial density, along with increased expression of genes involved in detoxifying reactive oxygen species (ROS) and mitophagy [57].

Therefore, it appears that imbalances in mitochondrial dynamics, mitophagy, and oxidative activity are the key contributing factors for cachexia. Of note, although downregulation of PGC-1 levels was reported in rats bearing AH-130 ascites tumors [58], PGC-1 levels were found to be unchanged in other cancer cachexia models [59–62]. Despite these inconsistent data, further information related to PGC-1 activation through AMPK-mediated phosphorylation and SIRT1 deacetylation are lacking in these experimental models.

### 2.5. Myostatin/Activin Pathway

Another pathway involved in protein hypercatabolism associated with muscle wasting is the myostatin/activin A pathway. Myostatin and activin A are transforming growth factor-beta (TGF- $\beta$ ) superfamily ligands that recognize two related transmembrane type I and type II serine/threonine kinase receptors to activate downstream signal transduction. Activation of the myostatin/activin A signaling pathway results in SMAD2 and SMAD3 phosphorylation [63], which regulates transcriptional responses leading to atrogenic activation in cancer cachexia [64–67] (Figure 2). Serum myostatin levels were inconsistently reported to be unchanged [68,69], increased [70], or reduced in sarcopenic versus young individuals [71]. Nevertheless, when a myostatin antagonist was administered to elderly mice, it resulted in an improvement in muscle regeneration during the onset of sarcopenia [72].

### 2.6. Decreased Regenerative Capacity

Satellite cell function and abundance significantly decline in sarcopenic conditions, and the progressive loss of regenerative capacity strongly impairs the function of the old skeletal muscle [73]. In cancer cachexia, muscle stem cells isolated from C26 tumor cell-bearing mice maintain the ability to proliferate and differentiate in vitro, but both their proliferation and differentiation potential were compromised in vivo [74]. These findings suggest that, in cancer cachexia, the muscle microenvironment affects and compromises the regenerative cues associated with healthy regeneration [75].

## 3. HDACs and Their Inhibitors

Histone post-translational modifications play a key role in gene transcription, shaping chromatin structures, and nuclear organization. One of the most relevant epigenetic signaling mechanisms in the differentiated tissue is ascribed to the balanced interplay between histone acetyltransferases (HATs) and HDACs, which tightly regulates the histone acetylation levels at regulatory regions (Figure 1a). In this context, HDACs remove acetyl groups from the lysines at the N-terminal tail of histones and promote a state of histone hypoacetylation that, in turn, relaxes the chromatin structure, ultimately hampering the progression of the transcriptional process. HATs and HDACs also target acetylated non-histone proteins, such as transcription factors, structural proteins, and enzymes, modulating their function in a different context [76]. Although HATs and HDACs belong to the class of chromatin writers, chromatin readers recognize acetylated lysines within histones or regulatory factors through protein modules, such as the bromodomains (BDs) (Figure 1b) [77]. Because of the key function of acetylation in gene transcription, HDACs and BD-containing proteins modulate a plethora of processes in physiological and pathological conditions, including development, cell growth and differentiation, and cancer [10].

In mammals, eighteen HDACs have been described that exploit two distinct catalytic mechanisms: 11 rely on zinc as a cofactor for their function and promote the hydrolysis of amide bonds using water as a nucleophile (HDAC1-11). In addition, seven sirtuins (1–7) utilize NAD<sup>+</sup> as a cofactor to transfer the acyl group to the ribose sugar at the C2 position. These two families are further divided into four classes: class I (HDAC1-3 and HDAC8), class IIa (HDAC4, HDAC5, HDAC7, and HDAC9), class IIb (HDAC6 and HDAC10), class III (sirtuin 1–7), and class IV (HDAC11) [78] (Figure 3a).

HDAC inhibitors are formed by a cap group, a linker part, and a Zn-binding group; they are further divided into two structural classes based on the zinc binding group: hydroxamic acids and aminoanilides. Examples of the hydroxamic-acid-type HDAC inhibitors are vorinostat (also known as suberoylanilide hydroxamic acid, SAHA) [79], belinostat (PXD101), givinostat, AR-42, and panobinostat (LBH589). In 2006, vorinostat became the first HDAC inhibitor to obtain FDA approval for the treatment of refractory primary cutaneous T-cell lymphoma [80].

Benzamides represent another category of synthetic HDAC inhibitors characterized by their bidentate coordination of the carbonyl oxygen and aniline nitrogen with the active site zinc cation. These compounds exhibit weaker metal binding affinity compared with hydroxamic acids and display distinctive kinetic behavior, including slow and tight binding to HDACs [8]. Clinical candidates from this group of synthetic HDAC inhibitors include tacedinaline, etinostat, mocetinostat, tucidinostat, domatinostat, and CXD [8].

Among the benzamides, tucidinostat (chidamide) is the only approved compound; it is authorized for use in treating patients with recurrent or refractory peripheral T-cell lymphoma [81].

In addition, short-chain fatty acid inhibitors include valproic acid and butyrate, whereas cyclic peptide inhibitors include the class I inhibitor romidepsin [82].

Additionally, several selective HDAC6 inhibitors, such as CKD-504, CKD-506, CS3003, HG116, and KA2507 are currently in phase I clinical trials [83] (Table 1).

**Table 1.** HDAC and BET inhibitors and their molecular targets.

Group	Compound	Molecule Target
HDAC inhibitor (hydroxamic acids)	Vorinostat (SAHA)	Class I, Class II, Class IV
	Trichostatin A (TSA)	Class I, Class II, Class IV
	Belinostat (PXD101)	Class I, Class II, Class IV
	Givinostat (ITF2357)	Class I, Class II
	AR-42	Class I, Class IIb
	Panobinostat (LBH689)	Class I, Class II, Class IV
HDAC inhibitor (benzamides)	Entinostat (MS-275)	Class I
	Mocetinostat	Class I and Class IV
	Chidamide	Class I HDAC1, HDAC2, HDAC3, and Class IIb HDAC10
	Tacedinaline	Class I
	Domatinostat	Class I
	Zabadinostat (CXD101)	HDAC1, HDAC2, and HDAC3
HDAC inhibitor (cyclic peptide)	Romidepsin	Class I
HDAC inhibitor (short chain fatty acid)	Valproic acid (VPA)	Class I, Class IIa
	Butyrate	Class I, Class IIa
HDAC inhibitor	CKD-504	HDAC6
	CKD-506	HDAC6
	CS3003	HDAC6
	HG116KA2507	HDAC6
BET inhibitor	JQ1	BET proteins
	PFI-1	BET proteins
	I-BET762	BET proteins
	OTX015	BET proteins
	CPI-0610	BET proteins
	RVX-208	BD2
	GSK778	BD1

#### 4. BET Proteins and Their Inhibitors

BDs are highly conserved protein interaction modules with a critical role in recognizing  $\epsilon$ -N-lysine acetylation motifs. The BET family of proteins is distinguished by the presence of two consecutive bromodomains and an additional terminal domain. The mammalian BET family encompasses BRDT, BRD2, BRD3, and BRD4 [84] (Figure 3b). These proteins possess the unique ability to specifically detect and bind to acetylated lysine residues, thereby influencing gene transcription. The most studied BET family member is BRD4, which is ubiquitously present in all tissues and has been widely studied in the cancer field because of its pivotal role in oncogene expression regulation through super-enhancer (SE) organization [85]. In addition to regulating transcription initiation through the association with transcription factors and chromatin regulators, BRD4 also interacts with transcription elongation complexes (P-TEFb) to govern the transcription of signal-inducible genes. It engages with P-TEFb, stimulating its kinase activity to phosphorylate RNA polymerase II and facilitating the resumption of transcription [86]. Of relevance to non-cancer related diseases, BRD4 plays a key role in the inflammatory response in sepsis and other conditions [87,88].

BET proteins have obtained increased attention in biomedical studies due to their exceptional susceptibility to potent and highly targeted inhibitors, making them an attractive target for drug development [89]. JQ1 is a thieno-triazolo-1,4-diazepin and the most extensively studied BET inhibitor [90–93]. BRD4, along with other members of the BET family, possesses an acetyl-lysine binding site capable of binding the acetylated lysines found on histone tails or proteins [94]. JQ1 can directly bind to this acetylated lysine binding site, fully occupying the entire binding pocket [94]. This binding is further stabilized through hydrophobic interactions with conserved BET residues. Intriguingly, in cell lines and animal models JQ1+ not only prevents BRD4 from interacting with acetylated residues, thus inhibiting its activity, but also displaces it from the chromatin [15,16,85,92]. JQ1 cannot be employed in clinical trials because of its poor pharmacokinetic profile and low oral bioavailability [95]. Thus, JQ1 analogs and derivatives have been developed that show better tolerance and minor toxicity [96], such as PFI-1, I-BET762, and OTX015 [97]. Although these human-suitable inhibitors display a better pharmacokinetic profile, they still present side effects in humans that restrict the dose escalation and, in some cases, lead to treatment discontinuation [98]. A second generation of BET inhibitors has been designed to reduce dose-limiting toxicity by selectively targeting one of the two BDs. Among this class, RVX-208 mainly blocks BD2 function [99], whereas GSK778 is a BD1 selective inhibitor [99]. CPI-0610 is another second-generation BET inhibitor with a molecular structure similar to JQ1. CPI-0610 is currently in phase 3 clinical trials for myelofibrosis (NCT04603495) and displays higher potency and selectivity and reduced toxicity than the first-generation compounds [100–102].

Importantly, whereas the BD1 and BD2 second-generation inhibitors are effective in blocking cell proliferation and cell survival in cancer models, BD2-selective inhibitors are largely ineffective [99]. Conversely, BD2-selective inhibitors ameliorate inflammatory diseases in preclinical models [99] and are good candidates for inflammation-induced cardiac dysfunction and SARS-CoV-2 infection [103] (Table 1).

#### 5. How Are HDACs and BET Proteins Implicated in Sarcopenia and Cachexia?

HDACs have been shown to directly participate in the regulation of different transcriptional programs in the wasting skeletal muscle, such as in the transcriptional regulation of inflammation and oxidative stress genes, muscle regeneration, protein homeostasis, and mitochondrial function [104]. Thus, dysregulation of HDAC activity might exacerbate these processes, thereby accelerating muscle loss. Concurrently, HDAC pharmacological modulation may be beneficial in the attenuation of muscle loss.

In addition to histones, HDACs target non-histone proteins, e.g., transcription factors (Figure 1b). In the context of muscle mass regulation, acetylation of specific lysine residues can impact the cellular localization (activation/inactivation) of transcription factors such as FoxO1/3, signal transducer and activator of transcription (STAT)-1 and STAT3, NF- $\kappa$ B,



and the coactivator PGC-1 $\beta$ . For instance, Sirt1 blocks NF- $\kappa$ B activity by deacetylating the p65 subunit and preventing FoxO1/3 activation, thus reducing *atrogin 1* and *MuRF1* transcription [44]. PGC-1 $\beta$ , following AMPK dependent phosphorylation, is deacetylated by Sirt1, and this results in an increased nuclear localization and activation of its target genes [105].

BET proteins were shown to interact directly with acetylated transcription factors, such as the p65 subunit of NF- $\kappa$ B [19] and FoxO3 [18]; however, these interactions were not proven in skeletal muscle, nor were they reported to play a role in muscle wasting.

#### 5.1. HDACs and BET Proteins Regulate Skeletal Muscle Mass Maintenance

HDACs, and to a lesser extent BET proteins, have been reported to play a role in the regulation of muscle mass, either by regulating the expression of *atrogin 1*, *MuRF1*, and autophagy genes or modulating other catabolic signals, for instance the myostatin pathway.

HDAC1, 4, 5, 6, and SIRT1 have been proposed to play a critical role in regulating the onset and progression of skeletal muscle atrophy. For example, mRNA expression of *HDAC2*, *HDAC4*, *HDAC6*, and *SIRT1* is increased in the skeletal muscle of animals subjected to nutrient deprivation, denervation, or cast immobilization [106]. Only cast immobilization and denervation were associated with increased mRNA levels of *HDAC1* and *HDAC3*, whereas decreased levels of *HDAC7* and *HDAC9* were observed in different models of muscle atrophy [106].

HDAC1 favors FoxO activation during nutrient deprivation, and TSA treatment prevents muscle atrophy following starvation [106]. HDAC4, 5, and 7 recruit HDAC3, thereby causing deacetylation and activation of FoxO1/3 transcription factors and the subsequent transcriptional induction of pro-atrophy genes [107,108]. In addition, in myoblast cell lines and animal models, HDAC6 activates FoxO3a under the conditions of denervation muscle atrophy [109].

Overexpression of HDAC4 has been shown to reduce myofiber cross-sectional area, whereas its deletion improves the phenotype in denervated mouse muscles [110]. Similarly, HDAC6 is overexpressed during muscle wasting and its inactivation has been shown to protect against denervation-induced muscle atrophy [109]. HDACs have also been proposed to regulate the expression of atrogenes, such as the muscle-specific ubiquitin ligases *MuRF1* and *atrogin 1/MFbx*, by acting on two relevant transcription factors, myogenin and the FoxOs. In denervated muscles, HDAC4 was shown to interact with FoxO3 and to inhibit its degradation, thus enhancing FoxO3 signaling on its targets [111]. Acetylated FoxO3 is translocated from the nucleus to the cytoplasm and subsequently degraded; however, deacetylation increases transcriptional activity. Myogenin, an important muscle regulatory factor in late myogenesis, also participates in the induction of *atrogin 1/MFbx* during denervation, a process requiring HDAC4 [110].

Although the molecular mechanisms involving HDACs, FoxO3, *Atrogin 1/MFbx*, and *MuRF1* have not been specifically investigated in the context of cancer cachexia; they may fine tune the FoxO3 activity in skeletal muscle during cancer cachexia as well.

In old rats, HDAC4 levels are mildly decreased in gastrocnemius with aging but are significantly upregulated in a model of disuse atrophy [112]. In normal conditions, HDCA5 modulates TFEB-mediated *MuRF1* transcriptional activation in mouse skeletal muscle, whereas angiotensin II promotes muscle atrophy favoring HDAC5 cytoplasmic translocation and *MuRF1* expression through TFEB. This pathway may play a role in angiotensin-II-induced muscle atrophy in congestive heart failure patients [113].

The class I and II HDAC inhibitor TSA prevents the increase in *MuRF1* expression in the soleus in a model of unloading-induced muscle atrophy [114].

TSA also promotes an induction of follistatin, an antagonist of myostatin, that promotes an increase in muscle mass and strength [115]. Myostatin, *MuRF1*, and *Atrogin 1* levels are also reduced by BET inhibition through the small molecule JQ1 in C2C12 myotubes in an in vitro model of dexamethasone-induced atrophy [116].

Sirt1 has been linked to improved metabolic function in the aging skeletal muscle. For instance, Sirt1 stimulates the activity of PGC-1 through deacetylation [117] and thus protects against sarcopenia. Additionally, supplementation with an NAD<sup>+</sup> precursor as a Sirt1 cofactor has demonstrated protective effects against age-related metabolic alterations in the skeletal muscle of animal models in a Sirt1-dependent manner [118]. Sirt1 also promotes FoxO1 and FoxO3a deacetylation in vivo and in vitro and decreases FoxO protein activity in fasted mice [44]. On the other hand, FoxO1 and FoxO3a are activated by HDAC1, which induces the muscle atrophy associated with muscle disuse [106]. Sirt1 also negatively modulates the transcriptional activation mediated by the NF- $\kappa$ B transcription factor by deacetylating the lysine 310 of the p65 subunit, thus reducing its transcriptional ability. This axis has been proposed to play a role in cancer cachexia through the regulation of the Nox4 subunit and oxidative stress [119]. However, in the muscle of old rats, a TNF increase does not upregulate p65 protein levels or NF- $\kappa$ B's DNA-binding ability [120].

Despite this line of evidence suggesting multiple regulatory roles for HDACs in muscle atrophy, knowledge is lacking regarding their specific functions and the underlying molecular mechanisms in sarcopenia and cachexia.

In the C26 experimental model of cancer cachexia, oral administration of the class I (HDAC1, 2, 3, and 8) and IIb (HDAC6 and 8) AR-42 inhibitor extended survival significantly, while preventing the loss of muscle and fat tissue mass, preserving muscle fiber size, and enhancing muscle strength. Additionally, AR-42 hindered the upregulation of MuRF1 and atrogen-1 mRNA levels. Although AR-42 treatment did not affect serum TNF levels in C26-tumor-bearing mice, it reduced levels of serum IL-6 and intramuscular IL-6 mRNA expression [121] (Figure 2). This anti-cachectic effect was reproduced in the Lewis lung cancer cachexia model but, notably, it was not observed following administration of the class I, II, and IV inhibitor vorinostat or the class I inhibitor romidepsin [121], as well as of the class I and IIa inhibitor valproic acid (VPA) and the class I, II, and IV inhibitor TSA [122,123]. These findings suggest that AR-42's effects are mediated by specific interactions with multiple transcriptional regulators or, alternatively, this compound may specifically block HDAC activity in certain regulatory complexes containing HDACs. Further investigations are warranted to better characterize the molecular mechanism underlying muscle preservation following AR-42 treatment in tumor-bearing mice.

A more recent study reported that higher doses of valproic acid ameliorates muscle wasting in the C26 and LLC experimental models. In fact, in the C26 and LLC experimental models of cancer cachexia, VPA treatment preserved the muscle mass and cross-sectional area in TA muscles. Following VPA treatment, muscles displayed reduced levels of CCAAT/enhancer binding protein beta (C/EBP $\beta$ ), which is necessary for Atrogen 1 upregulation in tumor-bearing mice. Interestingly, VPA does not have any impact on FoxO activity in this model. Overall, VPA treatment also improved pAkt/Akt and p-S6/S6 ratio, suggesting that it enhances protein synthesis and attenuates protein catabolism in muscles from tumor-bearing mice [124] (Figure 2).

The impact of HDACs and their inhibitors in the aging muscle has not been extensively studied. One report shows that mice fed with a butyrate-containing diet for 10 months, starting at 16 months of age, exhibited increased mitochondrial biogenesis in the skeletal muscle of old mice and a reduction in the markers of oxidative stress. The increased muscle mass was not due to a reduction in E3-ligase-mediated proteasomal degradation [125] (Figure 2).

Atrogen expression was shown to also be dependent on BRD4 and BRD2 in muscle from C26-tumor-bearing mice. Administration of the BET inhibitor JQ1 in this experimental model of cancer cachexia prevented weight loss and spared muscle and adipose tissues, extending survival without impacting directly on tumor growth. At the onset of cancer cachexia, the increased FoxO3 recruitment and histone acetylation facilitated the association of BRD4 at pro-atrophy genes, promoting their RNA-Pol-II-mediated transcription. Increased FoxO3 occupancy at pro-atrophic genes such as *MuRF1*, *M Fbx/atrogen-1*, and *G B R PL1* is facilitated by AMPK-mediated FoxO3 phosphorylation, which in turn is

induced by elevated systemic IL-6 levels and AMPK activation in skeletal muscle (Figure 2). Additionally, BRD4 and BRD2 are directly involved in the transcriptional regulation of *IL-6* and the parathyroid-hormone-related protein *PTHrP* in C26 tumors. Following JQ1 treatment, the expression of *IL-6* and *PTHrP* in C26-cell-derived tumors is diminished, indicating that JQ1 also alters the tumor transcriptional program, preventing the upregulation of pro-cachectic factors without affecting tumor mass [15].

JQ1 treatment in aged mice reduced the extracellular matrix upregulation in skeletal muscle and fibrogenic conversion of satellite cells, also restoring their myogenic differentiation potential [126]. In addition, BRD4 was shown to occupy the chromatin regulatory regions of NADPH oxidase subunits in the mdx muscle. This increased association led to elevated levels of reactive oxygen species (ROS), inflammation, fibrosis, and necrosis [16]. The administration of JQ1 has been shown to effectively reduce NADPH subunit transcript levels and ameliorate the phenotype of mdx mice [16].

Because of the key roles played by oxidative stress, inflammation, and fibrosis in sarcopenia, pharmacological blockade of BET proteins may also target these processes when they are involved in the aging skeletal muscle.

Overall, this line of evidence suggests that further preclinical studies on the impact of multiple HDAC and BET inhibitors are necessary to better dissect the impact of these drugs on the progression of cancer cachexia and sarcopenia. For instance, little is known about the role of HDAC and BET inhibitor administration on neuromuscular junctions and the decline of motor neurons or on the mitochondrial dysfunctions observed in sarcopenia.

## 5.2. Epigenetics—Metabolism Crosstalk in Cachexia and Sarcopenia

Muscle wasting with disrupted metabolic homeostasis is a hallmark of cachexia and sarcopenia. Chronic exposure to factors causing muscle exhaustion, such as inflammatory factors and mitochondrial dysfunction in disease-induced cachexia and aging-related sarcopenia, results in metabolic reprogramming. This process is closely intertwined with epigenetics [127], which connects environmental factors and genetics in an individual's phenotype. However, the crosstalk between epigenetics and metabolism in muscle wasting remains partly unclear, especially regarding causality, disease trajectory, and therapy perspectives.

The mechanisms underlying the disturbed metabolism in muscle atrophy include either anabolic resistance with diminished protein synthesis in sarcopenia or accelerated protein degradation in cachexia [128]. Other metabolic alterations that may occur, especially in cancer cachexia, are accelerated glucose production following excess lactate secretion by the tumor, which supports tumor growth, and increased lipolysis triggered by inflammatory factors [129]. These adaptations modify the cellular concentrations and fluxes of intermediate metabolites that are utilized as substrates and cofactors in subsequent epigenetic modifications, generating a bi-directional crosstalk between metabolic adaptation and epigenetics. The most relevant metabolites in this crosstalk include acetyl-CoA, nicotinamide adenine dinucleotide (NAD<sup>+</sup>),  $\alpha$ -ketoglutarate, and S-adenosylmethionine (SAM). Acetyl-CoA and NAD<sup>+</sup> play crucial roles in regulating the acetylation status of histones. Acetyl-CoA is at the center of glucose and lipid metabolism and its concentration reflects the cellular metabolic state. It maintains cell's acetylation capacity by donating acetyl groups for histones in a reaction catalyzed by histone acetyltransferases (HATs) [130]. Similarly, NAD<sup>+</sup> operates at the core of the energy conversion processes in the TCA cycle and OXPHOS but also functions as a substrate for sirtuins (SIRT6). The equilibrium between the HAT and HDAC activities is responsible for the conformational changes in chromatin with transcription activation (chromatin open) and inactivation (chromatin closed) capabilities, respectively. NAD<sup>+</sup> regulates mitochondrial metabolism and promotes sirtuin activity, whereas muscle NAD<sup>+</sup> depletion has been reported in cachectic mice and sarcopenic humans [53,131]. Therefore, NAD<sup>+</sup> loss in muscle atrophy may result in sirtuin deactivation and pronounced histone acetylation, alongside a disturbed gene expression profile. We recently showed that NAD<sup>+</sup> precursor therapies, on the other hand, are promis-


ing approaches for muscle wasting conditions [131], although a clear demonstration of the contribution of NAD<sup>+</sup> repletion to the epigenetic control of muscle metabolism is lacking and the scant data available only allow speculation on potential mechanisms. For instance, in cachectic mice, NAD<sup>+</sup> repletion with niacin slightly increased the mRNA expression of the mitochondrial Sirt3 but the enzymatic activity of sirtuin was not determined. Similarly, some indications of changes in DNA methylation (discussed below) upon nicotinamide riboside were reported in a population of mostly obese individuals [132], supporting the concept that the NAD<sup>+</sup> status takes part in the control of muscle epigenetic regulatory processes.

One-carbon metabolism provides another metabolic regulatory point for epigenetic modifications. It connects metabolism of amino acids, specifically methionine, serine and glycine, to the methionine cycle to provide methyl groups for post-transcriptional modifications [133]. These amino acids are utilized to produce SAM. With the help of DNA methyltransferases (DNMTs), SAM provides a methyl group for DNA regions with CpG sites, which usually prevent the binding of transcription factors and other proteins, leading to repressed gene expression. Conversely, DNA demethylation occurs via the TCA cycle intermediate  $\alpha$ -ketoglutarate and is mediated dioxygenases [134]. Few reports have been published regarding methylation in muscle atrophy and especially cachexia. In sarcopenic men, muscle methylome was significantly altered, especially in genes participating in oxidative phosphorylation and myogenesis [135]. Furthermore, inhibition of enhancer of zeste homologue 2 (EZH2), a histone methyltransferase and one of the differentially expressed targets in sarcopenia, impacted the methylation of OXPHOS-related genes and improved mitochondrial respiration in human primary myoblasts [135].

If the causal relationship between the metabolic alterations and the epigenome status still requires some solid demonstrations, a strong line of evidence exists linking the modulation of epigenetics and the consequent impact on muscle metabolism. Indeed, HDACs provide a therapeutic target for sarcopenia and cachexia, given that many HDACs participate in the regulation of muscle mass and metabolism in wasting conditions [136]. The inhibition of HDAC activity has resulted in improvements, for example, with AR-42 in C26-tumor-bearing mice [137] and with entinostat in cardiac complications in rodent cachexia [138]. In addition to the control of processes regulating muscle atrophy, HDACs can modify the expression of critical metabolic enzymes; a recent review highlights the most relevant metabolic pathways regulated by HDACs [139]. For example, class II HDACs induce gluconeogenic enzyme G6Pase expression [108], while also triggering their other downstream target FoxO, a transcription factor associated with muscle protein degradation and autophagy [140], providing another link between epigenetic regulation and metabolism for muscle atrophy. Consistently, knocking out a facilitator of HDAC activity, NCoR1, increased muscle mass and promoted exercise capacity in mice [141]. As a consequence, HDAC inhibitors simultaneously act on protein and energy metabolism, potentially targeting distinct aspects of muscle wasting. As an example, butyrate, beyond interfering with myostatin-induced protein hypercatabolism, improves glucose metabolism in aged mice [125].

Considering epigenetics from a broader perspective, non-coding RNAs, especially miRNAs, participate in muscle mass regulation [142]. Changes in several micro-RNAs have been described in muscle atrophy conditions [143,144]. However, little focus has been afforded to investigate their role in mediating metabolic reactions. Although miRNAs have been suggested to function as biomarkers and potential therapeutic targets for cachexia and sarcopenia [145], to date, the only therapeutic study targeting skeletal muscle has been miR-23a/27a delivery, which preserved muscle mass in mice with diabetes-induced cachexia [146].

Overall, the importance of muscle metabolism in controlling muscle mass and function is growing and the specific pathways associated with the epigenetic status (Figure 4) are being elucidated; these factors could lead to the identification of prospective epigenetic drugs to counteract the metabolic dysfunction underlying sarcopenia and cachexia.



**Figure 4.** Simplified illustration of the connections between intermediate metabolites and epigenetic regulation. Epigenetic processes are written in upper case and highlighted with white boxes. Crucial metabolites for epigenetic modifications are highlighted with blue boxes. Metabolic pathways are written in italics. Abbreviations—3-PG: 3-phosphoglyceric acid; Acetyl-CoA: acetyl coenzyme A; NAD<sup>+</sup>: nicotinamide adenine dinucleotide; NADH: nicotinamide adenine dinucleotide, reduced form; -KG: alpha ketoglutarate; TCA cycle: tricarboxylic acid cycle; HATs: histone acetyltransferases; HDACs: histone deacetylases; TETs: ten eleven translocases, i.e., -KG-dependent dioxygenases; SAM: S-adenosylmethionine; SAH: S-adenosylhomocysteine; DNMTs: DNA methyltransferases. Image created with PowerPoint and Smart Servier.

## 6. HDACs and BET Proteins in Skeletal Muscle Regeneration in Cachexia and Sarcopenia

HDACs can influence the differentiation of muscle precursor cells into mature muscle fibers. Altered HDAC activity might impede the regenerative potential of muscle tissue, contributing to the progression of sarcopenia. Impaired regeneration has been suggested as a potential factor contributing to the muscle loss observed in cancer cachexia. In fact, muscle tissues from tumor-bearing mice have been reported to show an accumulation of Pax7+ myogenic precursors that are unable to efficiently differentiate into myotubes [147,148]. Likewise, sarcopenic muscles experience a reduction in the number and function of muscle stem cells [73,149,150].

HDAC1 has been extensively shown to play a role in regulating myogenesis: TSA, VPA, and butyrate increase the differentiation potential of C2C12 myoblasts by promoting MyoD acetylation and modulating histone acetylation at specific gene promoters [150].

HDAC4, HDAC5, HDAC7, and HDAC9, which are categorized as class IIa HDACs, have been implicated in the regulation of myogenesis through their impact on myocyte enhancer factor 2 (MEF2) [151,152]. These HDACs physically interact with MEF2 [153] (Figure 3) and act to hinder the differentiation of myoblasts. Remarkably, the repression of MEF2 by class IIa HDACs occurs independently of their deacetylase activity, suggesting that the effects of HDACs are mediated by the recruitment of co-repressors or the exclusion of transcriptional activators [154,155].

Notably, both BRD3 and BRD4 play roles in regulating skeletal myogenesis. In differentiating C2C12 myoblasts, BRD4 knockdown is essential for myogenic differentiation,

whereas downregulation of BRD3 enhances myogenic differentiation [156]. Roberts and colleagues demonstrated that BET inhibitor compounds hinder myogenic differentiation across various cell models. The inhibitory impact of pan-BET inhibitors on myogenesis was replicated by specifically depleting BRD4 through RNA interference and offered initial proof of the significant roles played by BET proteins, especially BRD4, in myogenic differentiation. This indicates the potential involvement of BRD4 in activating the muscle transcription program, potentially by binding to hyperacetylated pro-myogenic enhancers and/or promoters [156].

## 7. Conclusions

The current body of evidence, based on the initial use of HDAC and BET inhibitors in experimental models of sarcopenia and cachexia along with preliminary experiments conducted in models of muscle disuse and denervation, suggests that these two classes of inhibitors warrant further investigation to assess their full potential as a therapeutic avenue in the treatment of cachexia and sarcopenia. As newly developed inhibitors with improved safety profiles are tested, it is essential to comprehensively evaluate their long-term effects. Furthermore, it is relevant to assess the impact of second-generation BD-specific inhibitors in the context of cachexia and sarcopenia and determine which isoform-specific HDAC inhibitors are most effective in mitigating muscle wasting. Dual BET/HDAC inhibitor treatment may also have the potential to address multiple processes contributing to muscle loss simultaneously, keeping in mind that both cancer cachexia and aging sarcopenia are multifactorial and multiorgan syndromes that likely require the targeting of multiple pathways to obtain a clinically relevant phenotypical effect.

Furthermore, whereas a crosstalk between muscle and bone changes has been described both in cachexia [157,158] and sarcopenia [159,160], our understanding of how epigenetic factors influence the regulation of the muscle/bone interaction in muscle wasting remains quite limited.

HDAC inhibitors suppress osteoblastic progenitors and thus might not represent an effective approach for addressing conditions related to bone aging or cachexia, such as osteopenia and osteoporosis. In these conditions, maintaining a healthy reservoir of stem and progenitor cells is crucial for the generation of new bone tissue, and HDACs could potentially exacerbate the process of osteoclastogenesis. Current evidence hints at the possibility that selective inhibitors targeting HDAC6 [161] and activators of SIRT6 could potentially stimulate bone formation or prevent bone loss [162]. However, further research is necessary to unravel the precise mechanisms underpinning these observed effects [163]. On the other hand, BET inhibitors have been shown to block osteoclastic activity and prevent the bone loss caused by ovariectomy (OVX) in vivo [164], suggesting that the pharmacological blockade of BET proteins may represent a therapeutic avenue for osteoporosis.

At the molecular level, a more precise evaluation of the genome-wide distribution of HDACs and BET proteins in skeletal muscle during cachexia and sarcopenia will enable us to uncover novel regulatory circuits and gene categories that are directly regulated by these chromatin factors. This insight will help us better understand the modulation of these gene categories following treatments with epigenetic inhibitors. Furthermore, a more in-depth exploration of the interaction between HDACs or BET proteins and acetylated proteins that play a crucial role in muscle wasting, such as FoxO, p65/NF- $\kappa$ B, STAT1/3, and PGC-1, may reveal novel regulatory dynamics mediated by the interaction of acetylated transcription factors and BET bromodomains, extending their relevance beyond histones.

**Funding:** This research was funded by Fondazione Cariplo, grant number 2017-0604 to G.C. and F.P. and AIRC-IG 21353 to G.C.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Bodine, S.C.; Latres, E.; Baumhueter, S.; Lai, V.K.; Nunez, L.; Clarke, B.A.; Poueymirou, W.T.; Panaro, F.J.; Na, E.; Dharmarajan, K.; et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. *Science* **2001**, *294*, 1704–1708. [[CrossRef](#)]
2. Deutz, N.E.P.; Ashurst, I.; Ballesteros, M.D.; Bear, D.E.; Cruz-Jentoft, A.J.; Genton, L.; Landi, F.; Laviano, A.; Norman, K.; Prado, C.M. The Underappreciated Role of Low Muscle Mass in the Management of Malnutrition. *J. m. Med. Dir. ssoc.* **2019**, *20*, 22–27. [[CrossRef](#)]
3. Campins, L.; Camps, M.; Riera, A.; Pleguezuelos, E.; Yebenes, J.C.; Serra-Prat, M. Oral Drugs Related with Muscle Wasting and Sarcopenia. A Review. *Pharmacology* **2017**, *99*, 1–8. [[CrossRef](#)] [[PubMed](#)]
4. Cohen, S.; Nathan, J.A.; Goldberg, A.L. Muscle wasting in disease: Molecular mechanisms and promising therapies. *Nat. Rev. Drug Discov.* **2015**, *14*, 58–74. [[CrossRef](#)] [[PubMed](#)]
5. Fearon, K.C.; Glass, D.J.; Guttridge, D.C. Cancer cachexia: Mediators, signaling, and metabolic pathways. *Cell Metab.* **2012**, *16*, 153–166. [[CrossRef](#)]
6. Fernandes, L.V.; Paiva, A.E.G.; Silva, A.C.B.; de Castro, I.C.; Santiago, A.F.; de Oliveira, E.P.; Porto, L.C.J. Prevalence of sarcopenia according to EWGSOP1 and EWGSOP2 in older adults and their associations with unfavorable health outcomes: A systematic review. *ging Clin. Exp. Res.* **2022**, *34*, 505–514. [[CrossRef](#)]
7. Mercuri, E.; Bonnemann, C.G.; Muntoni, F. Muscular dystrophies. *Lancet* **2019**, *394*, 2025–2038. [[CrossRef](#)]
8. Nepali, K.; Liou, J.P. Recent developments in epigenetic cancer therapeutics: Clinical advancement and emerging trends. *J. Biomed. Sci.* **2021**, *28*, 27. [[CrossRef](#)]
9. Minetti, G.C.; Colussi, C.; Adami, R.; Serra, C.; Mozzetta, C.; Parente, V.; Fortuni, S.; Straino, S.; Sampaolesi, M.; Di Padova, M.; et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. *Nat. Med.* **2006**, *12*, 1147–1150. [[CrossRef](#)] [[PubMed](#)]
10. Guo, J.; Zheng, Q.; Peng, Y. BET proteins: Biological functions and therapeutic interventions. *Pharmacol. Ther.* **2023**, *243*, 108354. [[CrossRef](#)]
11. Bettica, P.; Petrini, S.; D’Oria, V.; D’Amico, A.; Catteruccia, M.; Pane, M.; Sivo, S.; Magri, F.; Brajkovic, S.; Messina, S.; et al. Histological effects of givinostat in boys with Duchenne muscular dystrophy. *Neuromuscul. Disord.* **2016**, *26*, 643–649. [[CrossRef](#)] [[PubMed](#)]
12. Consalvi, S.; Mozzetta, C.; Bettica, P.; Germani, M.; Fiorentini, F.; Del Bene, F.; Rocchetti, M.; Leoni, F.; Monzani, V.; Mascagni, P.; et al. Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat. *Mol. Med.* **2013**, *19*, 79–87. [[CrossRef](#)] [[PubMed](#)]
13. Sandona, M.; Cavioli, G.; Renzini, A.; Cedola, A.; Gigli, G.; Coletti, D.; McKinsey, T.A.; Moresi, V.; Saccone, V. Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular Dystrophies. *Int. J. Mol. Sci.* **2023**, *24*, 4306. [[CrossRef](#)] [[PubMed](#)]
14. Campbell, A.E.; Oliva, J.; Yates, M.P.; Zhong, J.W.; Shadle, S.C.; Snider, L.; Singh, N.; Tai, S.; Hiramuki, Y.; Tawil, R.; et al. BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells. *Skelet. Muscle* **2017**, *7*, 16. [[CrossRef](#)]
15. Segatto, M.; Fittipaldi, R.; Pin, F.; Sartori, R.; Dae Ko, K.; Zare, H.; Fenizia, C.; Zanchettin, G.; Pierobon, E.S.; Hatakeyama, S.; et al. Epigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival. *Nat. Commun.* **2017**, *8*, 1707. [[CrossRef](#)]
16. Segatto, M.; Szokoll, R.; Fittipaldi, R.; Bottino, C.; Nevi, L.; Mamchaoui, K.; Filippakopoulos, P.; Caretti, G. BETs inhibition attenuates oxidative stress and preserves muscle integrity in Duchenne muscular dystrophy. *Nat. Commun.* **2020**, *11*, 6108. [[CrossRef](#)]
17. Cruz-Jentoft, A.J.; Baeyens, J.P.; Bauer, J.M.; Boirie, Y.; Cederholm, T.; Landi, F.; Martin, F.C.; Michel, J.P.; Rolland, Y.; Schneider, S.M.; et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *ge geing* **2010**, *39*, 412–423. [[CrossRef](#)]
18. Liu, J.; Duan, Z.; Guo, W.; Zeng, L.; Wu, Y.; Chen, Y.; Tai, F.; Wang, Y.; Lin, Y.; Zhang, Q.; et al. Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer. *Nat. Commun.* **2018**, *9*, 5200. [[CrossRef](#)]
19. Huang, B.; Yang, X.D.; Zhou, M.M.; Ozato, K.; Chen, L.F. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. *Mol. Cell Biol.* **2009**, *29*, 1375–1387. [[CrossRef](#)]
20. Ali, S.; Garcia, J.M. Sarcopenia, cachexia and aging: Diagnosis, mechanisms and therapeutic options—A mini-review. *Gerontology* **2014**, *60*, 294–305. [[CrossRef](#)]
21. Tuttle, C.S.L.; Thang, L.A.N.; Maier, A.B. Markers of inflammation and their association with muscle strength and mass: A systematic review and meta-analysis. *ging Res. Rev.* **2020**, *64*, 101185. [[CrossRef](#)]
22. Schaap, L.A.; Pluijm, S.M.; Deeg, D.J.; Harris, T.B.; Kritchevsky, S.B.; Newman, A.B.; Colbert, L.H.; Pahor, M.; Rubin, S.M.; Tylavsky, F.A.; et al. Higher inflammatory marker levels in older persons: Associations with 5-year change in muscle mass and muscle strength. *J. Gerontol. Biol. Sci. Med. Sci.* **2009**, *64*, 1183–1189. [[CrossRef](#)] [[PubMed](#)]
23. Lecker, S.H.; Solomon, V.; Mitch, W.E.; Goldberg, A.L. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. *J. Nutr.* **1999**, *129*, 227S–237S. [[CrossRef](#)] [[PubMed](#)]
24. Gomes, M.D.; Lecker, S.H.; Jagoe, R.T.; Navon, A.; Goldberg, A.L. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. *Proc. Natl. cad. Sci. US* **2001**, *98*, 14440–14445. [[CrossRef](#)]

25. Milan, G.; Romanello, V.; Pescatore, F.; Armani, A.; Paik, J.H.; Frasson, L.; Seydel, A.; Zhao, J.; Abraham, R.; Goldberg, A.L.; et al. Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy. *Nat. Commun.* **2015**, *6*, 6670. [[CrossRef](#)]
26. Sandri, M.; Sandri, C.; Gilbert, A.; Skurk, C.; Calabria, E.; Picard, A.; Walsh, K.; Schiaffino, S.; Lecker, S.H.; Goldberg, A.L. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. *Cell* **2004**, *117*, 399–412. [[CrossRef](#)]
27. Ladner, K.J.; Caligiuri, M.A.; Guttridge, D.C. Tumor necrosis factor-regulated biphasic activation of NF-kappa B is required for cytokine-induced loss of skeletal muscle gene products. *J. Biol. Chem.* **2003**, *278*, 2294–2303. [[CrossRef](#)] [[PubMed](#)]
28. Bonetto, A.; Aydogdu, T.; Kunzevitzky, N.; Guttridge, D.C.; Khuri, S.; Koniaris, L.G.; Zimmers, T.A. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. *PLoS ONE* **2011**, *6*, e22538. [[CrossRef](#)]
29. Altun, M.; Besche, H.C.; Overkleeft, H.S.; Piccirillo, R.; Edelmann, M.J.; Kessler, B.M.; Goldberg, A.L.; Ulfhake, B. Muscle wasting in aged, sarcopenic rats is associated with enhanced activity of the ubiquitin proteasome pathway. *J. Biol. Chem.* **2010**, *285*, 39597–39608. [[CrossRef](#)]
30. Clavel, S.; Coldefy, A.S.; Kurkdjian, E.; Salles, J.; Margaritis, I.; Derijard, B. Atrophy-related ubiquitin ligases, atrogin-1 and MuRF1 are up-regulated in aged rat Tibialis Anterior muscle. *Mech. Ageing Dev.* **2006**, *127*, 794–801. [[CrossRef](#)]
31. Welle, S.; Brooks, A.I.; Delehanty, J.M.; Needler, N.; Thornton, C.A. Gene expression profile of aging in human muscle. *Physiol. Genomics* **2003**, *14*, 149–159. [[CrossRef](#)] [[PubMed](#)]
32. Edstrom, E.; Altun, M.; Hagglund, M.; Ulfhake, B. Atrogin-1/MAFbx and MuRF1 are downregulated in aging-related loss of skeletal muscle. *J. Gerontol. Biol. Sci. Med. Sci.* **2006**, *61*, 663–674. [[CrossRef](#)]
33. Sandri, M.; Barberi, L.; Bijlsma, A.Y.; Blaauw, B.; Dyar, K.A.; Milan, G.; Mammucari, C.; Meskers, C.G.; Pallafacchina, G.; Paoli, A.; et al. Signalling pathways regulating muscle mass in ageing skeletal muscle: The role of the IGF1-Akt-mTOR-FoxO pathway. *Biogerontology* **2013**, *14*, 303–323. [[CrossRef](#)]
34. Jager, S.; Handschin, C.; St-Pierre, J.; Spiegelman, B.M. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. *Proc. Natl. Acad. Sci. US* **2007**, *104*, 12017–12022. [[CrossRef](#)] [[PubMed](#)]
35. Wohlgemuth, S.E.; Seo, A.Y.; Marzetti, E.; Lees, H.A.; Leeuwenburgh, C. Skeletal muscle autophagy and apoptosis during aging: Effects of calorie restriction and life-long exercise. *Exp. Gerontol.* **2010**, *45*, 138–148. [[CrossRef](#)] [[PubMed](#)]
36. Carter, H.N.; Kim, Y.; Erlich, A.T.; Zarrin-Khat, D.; Hood, D.A. Autophagy and mitophagy flux in young and aged skeletal muscle following chronic contractile activity. *J. Physiol.* **2018**, *596*, 3567–3584. [[CrossRef](#)] [[PubMed](#)]
37. Kang, S.H.; Lee, H.A.; Kim, M.; Lee, E.; Sohn, U.D.; Kim, I. Forkhead box O3 plays a role in skeletal muscle atrophy through expression of E3 ubiquitin ligases MuRF-1 and atrogin-1 in Cushing's syndrome. *m. J. Physiol. Endocrinol. Metab.* **2017**, *312*, E495–E507. [[CrossRef](#)] [[PubMed](#)]
38. Ninfali, C.; Siles, L.; Darling, D.S.; Postigo, A. Regulation of muscle atrophy-related genes by the opposing transcriptional activities of ZEB1/CtBP and FOXO3. *Nucleic Acids Res.* **2018**, *46*, 10697–10708. [[CrossRef](#)] [[PubMed](#)]
39. Mosoni, L.; Valluy, M.C.; Serrurier, B.; Prugnaud, J.; Obled, C.; Guezennec, C.Y.; Mirand, P.P. Altered response of protein synthesis to nutritional state and endurance training in old rats. *m. J. Physiol.* **1995**, *268*, E328–E335. [[CrossRef](#)]
40. Katsanos, C.S.; Kobayashi, H.; Sheffield-Moore, M.; Aarsland, A.; Wolfe, R.R. Aging is associated with diminished accretion of muscle proteins after the ingestion of a small bolus of essential amino acids. *m. J. Clin. Nutr.* **2005**, *82*, 1065–1073. [[CrossRef](#)] [[PubMed](#)]
41. Cuthbertson, D.; Smith, K.; Babraj, J.; Leese, G.; Waddell, T.; Atherton, P.; Wackerhage, H.; Taylor, P.M.; Rennie, M.J. Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle. *FASEB J.* **2005**, *19*, 422–424. [[CrossRef](#)]
42. Volpi, E.; Mittendorfer, B.; Rasmussen, B.B.; Wolfe, R.R. The response of muscle protein anabolism to combined hyperaminoacidemia and glucose-induced hyperinsulinemia is impaired in the elderly. *J. Clin. Endocrinol. Metab.* **2000**, *85*, 4481–4490. [[CrossRef](#)]
43. Greer, E.L.; Dowlathshahi, D.; Banko, M.R.; Villen, J.; Hoang, K.; Blanchard, D.; Gygi, S.P.; Brunet, A. An AMPK-FOXO pathway mediates longevity induced by a novel method of dietary restriction in *C. elegans*. *Curr. Biol.* **2007**, *17*, 1646–1656. [[CrossRef](#)]
44. Lee, D.; Goldberg, A.L. SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth. *J. Biol. Chem.* **2013**, *288*, 30515–30526. [[CrossRef](#)] [[PubMed](#)]
45. Oexner, R.R.; Pla-Martín, D.; Paß, T.; Wiesen, M.H.J.; Zentis, P.; Schauss, A.; Baris, O.R.; Kimoloi, S.; Wiesner, R.J. Extraocular Muscle Reveals Selective Vulnerability of Type IIB Fibers to Respiratory Chain Defects Induced by Mitochondrial DNA Alterations. *Investig. Ophthalmol. Vis. Sci.* **2020**, *61*, 14. [[CrossRef](#)]
46. Rumsey, W.L.; Kendrick, Z.V.; Starnes, J.W. Bioenergetics in the aging Fischer 344 rat: Effects of exercise and food restriction. *Exp. Gerontol.* **1987**, *22*, 271–287. [[CrossRef](#)] [[PubMed](#)]
47. Gouspillou, G.; Bourdel-Marchasson, I.; Rouland, R.; Calmettes, G.; Biran, M.; Deschodt-Arsac, V.; Miraux, S.; Thiaudiere, E.; Pasdois, P.; Demaille, D.; et al. Mitochondrial energetics is impaired in vivo in aged skeletal muscle. *Ageing Cell* **2014**, *13*, 39–48. [[CrossRef](#)]
48. Conley, K.E.; Jubrias, S.A.; Esselman, P.C. Oxidative capacity and ageing in human muscle. *J. Physiol.* **2000**, *526 Pt 1*, 203–210. [[CrossRef](#)] [[PubMed](#)]
49. Canto, C.; Auwerx, J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. *Curr. Opin. Lipidol.* **2009**, *20*, 98–105. [[CrossRef](#)]



50. Kjøbsted, R.; Hingst, J.R.; Fentz, J.; Foretz, M.; Sanz, M.N.; Pehmøller, C.; Shum, M.; Marette, A.; Mounier, R.; Trebak, J.T.; et al. AMPK in skeletal muscle function and metabolism. *F SEB J.* **2018**, *32*, 1741–1777. [[CrossRef](#)]
51. Canto, C.; Gerhart-Hines, Z.; Feige, J.N.; Lagouge, M.; Noriega, L.; Milne, J.C.; Elliott, P.J.; Puigserver, P.; Auwerx, J. AMPK regulates energy expenditure by modulating NAD<sup>+</sup> metabolism and SIRT1 activity. *Nature* **2009**, *458*, 1056–1060. [[CrossRef](#)]
52. Yeo, D.; Kang, C.; Ji, L.L. Aging alters acetylation status in skeletal and cardiac muscles. *Geroscience* **2020**, *42*, 963–976. [[CrossRef](#)]
53. Migliavacca, E.; Tay, S.K.H.; Patel, H.P.; Sonntag, T.; Civiletto, G.; McFarlane, C.; Forrester, T.; Barton, S.J.; Leow, M.K.; Antoun, E.; et al. Mitochondrial oxidative capacity and NAD(+) biosynthesis are reduced in human sarcopenia across ethnicities. *Nat. Commun.* **2019**, *10*, 5808. [[CrossRef](#)]
54. Marzetti, E.; Calvani, R.; Cesari, M.; Buford, T.W.; Lorenzi, M.; Behnke, B.J.; Leeuwenburgh, C. Mitochondrial dysfunction and sarcopenia of aging: From signaling pathways to clinical trials. *Int. J. Biochem. Cell Biol.* **2013**, *45*, 2288–2301. [[CrossRef](#)] [[PubMed](#)]
55. Li, Y.; Jin, H.; Chen, Y.; Huang, T.; Mi, Y.; Zou, Z. Cancer cachexia: Molecular mechanism and pharmacological management. *Biochem. J.* **2021**, *478*, 1663–1688. [[CrossRef](#)] [[PubMed](#)]
56. Beltra, M.; Pin, F.; Ballaro, R.; Costelli, P.; Penna, F. Mitochondrial Dysfunction in Cancer Cachexia: Impact on Muscle Health and Regeneration. *Cells* **2021**, *10*, 3150. [[CrossRef](#)] [[PubMed](#)]
57. Zhang, Y.; Wang, J.; Wang, X.; Gao, T.; Tian, H.; Zhou, D.; Zhang, L.; Li, G. The autophagic-lysosomal and ubiquitin proteasome systems are simultaneously activated in the skeletal muscle of gastric cancer patients with cachexia. *m. J. Clin. Nutr.* **2020**, *111*, 570–579. [[CrossRef](#)]
58. Sandri, M.; Lin, J.; Handschin, C.; Yang, W.; Arany, Z.P.; Lecker, S.H.; Goldberg, A.L.; Spiegelman, B.M. PGC-1 $\alpha$  protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. *Proc. Natl. Acad. Sci. US* **2006**, *103*, 16260–16265. [[CrossRef](#)]
59. Ballaro, R.; Beltra, M.; De Lucia, S.; Pin, F.; Ranjbar, K.; Hulmi, J.J.; Costelli, P.; Penna, F. Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations. *F SEB J.* **2019**, *33*, 5482–5494. [[CrossRef](#)]
60. Brown, J.L.; Rosa-Caldwell, M.E.; Lee, D.E.; Blackwell, T.A.; Brown, L.A.; Perry, R.A.; Haynie, W.S.; Hardee, J.P.; Carson, J.A.; Wiggs, M.P.; et al. Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer cachexia in tumour-bearing mice. *J. Cachexia Sarcopenia Muscle* **2017**, *8*, 926–938. [[CrossRef](#)]
61. Pin, F.; Busquets, S.; Toledo, M.; Camperi, A.; Lopez-Soriano, F.J.; Costelli, P.; Argiles, J.M.; Penna, F. Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. *Oncotarget* **2015**, *6*, 43202–43215. [[CrossRef](#)]
62. Barreto, R.; Mandili, G.; Witzmann, F.A.; Novelli, F.; Zimmers, T.A.; Bonetto, A. Cancer and Chemotherapy Contribute to Muscle Loss by Activating Common Signaling Pathways. *Front. Physiol.* **2016**, *7*, 472. [[CrossRef](#)] [[PubMed](#)]
63. Sartori, R.; Milan, G.; Patron, M.; Mammucari, C.; Blaauw, B.; Abraham, R.; Sandri, M. Smad2 and 3 transcription factors control muscle mass in adulthood. *m. J. Physiol. Cell Physiol.* **2009**, *296*, C1248–C1257. [[CrossRef](#)] [[PubMed](#)]
64. Lokireddy, S.; McFarlane, C.; Ge, X.; Zhang, H.; Sze, S.K.; Sharma, M.; Kambadur, R. Myostatin induces degradation of sarcomeric proteins through a Smad3 signaling mechanism during skeletal muscle wasting. *Mol. Endocrinol.* **2011**, *25*, 1936–1949. [[CrossRef](#)]
65. Lokireddy, S.; Wijesoma, I.W.; Bonala, S.; Wei, M.; Sze, S.K.; McFarlane, C.; Kambadur, R.; Sharma, M. Myostatin is a novel tumoral factor that induces cancer cachexia. *Biochem. J.* **2012**, *446*, 23–36. [[CrossRef](#)]
66. McFarlane, C.; Vajjala, A.; Arigela, H.; Lokireddy, S.; Ge, X.; Bonala, S.; Manickam, R.; Kambadur, R.; Sharma, M. Negative auto-regulation of myostatin expression is mediated by Smad3 and microRNA-27. *PLoS ONE* **2014**, *9*, e87687. [[CrossRef](#)]
67. Zhou, X.; Wang, J.L.; Lu, J.; Song, Y.; Kwak, K.S.; Jiao, Q.; Rosenfeld, R.; Chen, Q.; Boone, T.; Simonet, W.S.; et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. *Cell* **2010**, *142*, 531–543. [[CrossRef](#)]
68. Ratkevicius, A.; Joyson, A.; Selmer, I.; Dhanani, T.; Grierson, C.; Tommasi, A.M.; DeVries, A.; Rauchhaus, P.; Crowther, D.; Alesci, S.; et al. Serum concentrations of myostatin and myostatin-interacting proteins do not differ between young and sarcopenic elderly men. *J. Gerontol. Biol. Sci. Med. Sci.* **2011**, *66*, 620–626. [[CrossRef](#)]
69. Ryan, A.S.; Li, G. Skeletal muscle myostatin gene expression and sarcopenia in overweight and obese middle-aged and older adults. *JCSM Clin. Rep.* **2021**, *6*, 137–142. [[CrossRef](#)]
70. Bergen, H.R.; Farr, J.N.; Vanderboom, P.M.; Atkinson, E.J.; White, T.A.; Singh, R.J.; Khosla, S.; LeBrasseur, N.K. Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: Insights using a new mass spectrometry-based assay. *Skelet. Muscle* **2015**, *5*, 21. [[CrossRef](#)] [[PubMed](#)]
71. Yarasheski, K.E.; Bhasin, S.; Sinha-Hikim, I.; Pak-Loduca, J.; Gonzalez-Cadavid, N.F. Serum myostatin-immunoreactive protein is increased in 60–92 year old women and men with muscle wasting. *J. Nutr. Health Aging* **2002**, *6*, 343–348. [[PubMed](#)]
72. Siriett, V.; Salerno, M.S.; Berry, C.; Nicholas, G.; Bower, R.; Kambadur, R.; Sharma, M. Antagonism of myostatin enhances muscle regeneration during sarcopenia. *Mol. Ther.* **2007**, *15*, 1463–1470. [[CrossRef](#)] [[PubMed](#)]
73. Sousa-Victor, P.; Munoz-Canoves, P. Regenerative decline of stem cells in sarcopenia. *Mol. Sp. Med.* **2016**, *50*, 109–117. [[CrossRef](#)] [[PubMed](#)]
74. Inaba, S.; Hinohara, A.; Tachibana, M.; Tsujikawa, K.; Fukada, S.I. Muscle regeneration is disrupted by cancer cachexia without loss of muscle stem cell potential. *PLoS ONE* **2018**, *13*, e0205467. [[CrossRef](#)] [[PubMed](#)]
75. Talbert, E.E.; Guttridge, D.C. Impaired regeneration: A role for the muscle microenvironment in cancer cachexia. *Semin. Cell Dev. Biol.* **2016**, *54*, 82–91. [[CrossRef](#)] [[PubMed](#)]
76. Narita, T.; Weinert, B.T.; Choudhary, C. Functions and mechanisms of non-histone protein acetylation. *Nat. Rev. Mol. Cell Biol.* **2019**, *20*, 156–174. [[CrossRef](#)] [[PubMed](#)]

77. Marmorstein, R.; Zhou, M.M. Writers and readers of histone acetylation: Structure, mechanism, and inhibition. *Cold Spring Harb. Perspect. Biol.* **2014**, *6*, a018762. [[CrossRef](#)]
78. Haberland, M.; Montgomery, R.L.; Olson, E.N. The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. *Nat. Rev. Genet.* **2009**, *10*, 32–42. [[CrossRef](#)]
79. Marks, P.A. Discovery and development of SAHA as an anticancer agent. *Oncogene* **2007**, *26*, 1351–1356. [[CrossRef](#)]
80. Siegel, D.; Hussein, M.; Belani, C.; Robert, F.; Galanis, E.; Richon, V.M.; Garcia-Vargas, J.; Sanz-Rodriguez, C.; Rizvi, S. Vorinostat in solid and hematologic malignancies. *J. Hematol. Oncol.* **2009**, *2*, 31. [[CrossRef](#)]
81. Rai, S.; Kim, W.S.; Ando, K.; Choi, I.; Izutsu, K.; Tsukamoto, N.; Yokoyama, M.; Tsukasaki, K.; Kuroda, J.; Ando, J.; et al. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Phase IIb results. *Haematologica* **2023**, *108*, 811–821. [[CrossRef](#)]
82. Brilli, L.L.; Swanhart, L.M.; de Caestecker, M.P.; Hukriede, N.A. HDAC inhibitors in kidney development and disease. *Pediatr. Nephrol.* **2013**, *28*, 1909–1921. [[CrossRef](#)]
83. Grivas, P.; Mortazavi, A.; Picus, J.; Hahn, N.M.; Milowsky, M.I.; Hart, L.L.; Alva, A.; Bellmunt, J.; Pal, S.K.; Bambury, R.M.; et al. Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. *Cancer* **2019**, *125*, 533–540. [[CrossRef](#)]
84. Taniguchi, Y. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins. *Int. J. Mol. Sci.* **2016**, *17*, 1849. [[CrossRef](#)] [[PubMed](#)]
85. Loven, J.; Hoke, H.A.; Lin, C.Y.; Lau, A.; Orlando, D.A.; Vakoc, C.R.; Bradner, J.E.; Lee, T.I.; Young, R.A. Selective inhibition of tumor oncogenes by disruption of super-enhancers. *Cell* **2013**, *153*, 320–334. [[CrossRef](#)] [[PubMed](#)]
86. Itzen, F.; Greifenberg, A.K.; Bosken, C.A.; Geyer, M. Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation. *Nucleic Acids Res.* **2014**, *42*, 7577–7590. [[CrossRef](#)]
87. Brown, J.D.; Lin, C.Y.; Duan, Q.; Griffin, G.; Federation, A.; Paranal, R.M.; Bair, S.; Newton, G.; Lichtman, A.; Kung, A.; et al. NF-kappaB directs dynamic super enhancer formation in inflammation and atherogenesis. *Mol. Cell* **2014**, *56*, 219–231. [[CrossRef](#)]
88. Wang, N.; Wu, R.; Tang, D.; Kang, R. The BET family in immunity and disease. *Signal Transduct. Target. Ther.* **2021**, *6*, 23. [[CrossRef](#)]
89. Schwalm, M.P.; Knapp, S. BET bromodomain inhibitors. *Curr. Opin. Chem. Biol.* **2022**, *68*, 102148. [[CrossRef](#)] [[PubMed](#)]
90. Belkina, A.C.; Nikolajczyk, B.S.; Denis, G.V. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. *J. Immunol.* **2013**, *190*, 3670–3678. [[CrossRef](#)]
91. Delmore, J.E.; Issa, G.C.; Lemieux, M.E.; Rahl, P.B.; Shi, J.; Jacobs, H.M.; Kastiris, E.; Gilpatrick, T.; Paranal, R.M.; Qi, J.; et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. *Cell* **2011**, *146*, 904–917. [[CrossRef](#)]
92. Filippakopoulos, P.; Picaud, S.; Mangos, M.; Keates, T.; Lambert, J.P.; Barsyte-Lovejoy, D.; Felletar, I.; Volkmer, R.; Muller, S.; Pawson, T.; et al. Histone recognition and large-scale structural analysis of the human bromodomain family. *Cell* **2012**, *149*, 214–231. [[CrossRef](#)]
93. Zuber, J.; Shi, J.; Wang, E.; Rappaport, A.R.; Herrmann, H.; Sison, E.A.; Magoon, D.; Qi, J.; Blatt, K.; Wunderlich, M.; et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. *Nature* **2011**, *478*, 524–528. [[CrossRef](#)]
94. Zaware, N.; Zhou, M.M. Bromodomain biology and drug discovery. *Nat. Struct. Mol. Biol.* **2019**, *26*, 870–879. [[CrossRef](#)] [[PubMed](#)]
95. Boi, M.; Gaudio, E.; Bonetti, P.; Kwee, I.; Bernasconi, E.; Tarantelli, C.; Rinaldi, A.; Testoni, M.; Cascione, L.; Ponzoni, M.; et al. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. *Clin. Cancer Res.* **2015**, *21*, 1628–1638. [[CrossRef](#)] [[PubMed](#)]
96. Divakaran, A.; Harki, D.A.; Pomerantz, W.C.K. Recent progress and structural analyses of domain-selective BET inhibitors. *Med. Res. Rev.* **2023**, *43*, 972–1018. [[CrossRef](#)] [[PubMed](#)]
97. Settleman, J. Cancer: Bet on drug resistance. *Nature* **2016**, *529*, 289–290. [[CrossRef](#)]
98. Postel-Vinay, S.; Herbschleb, K.; Massard, C.; Woodcock, V.; Soria, J.C.; Walter, A.O.; Ewerton, F.; Poelman, M.; Benson, N.; Ocker, M.; et al. First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: Emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity. *Eur. J. Cancer* **2019**, *109*, 103–110. [[CrossRef](#)]
99. Gilan, O.; Rioja, I.; Knezevic, K.; Bell, M.J.; Yeung, M.M.; Harker, N.R.; Lam, E.Y.N.; Chung, C.W.; Bamborough, P.; Petretich, M.; et al. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. *Science* **2020**, *368*, 387–394. [[CrossRef](#)] [[PubMed](#)]
100. Trojer, P. Targeting BET Bromodomains in Cancer. *Annu. Rev. Cancer Biol.* **2022**, *6*, 313–336. [[CrossRef](#)]
101. Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (MANIFEST-2). Available online: <https://www.clinicaltrials.gov/study/NCT04603495> (accessed on 27 October 2023).
102. Harrison, C.N.; Gupta, V.K.; Gerds, A.T.; Rampal, R.; Verstovsek, S.; Talpaz, M.; Kiladjian, J.J.; Mesa, R.; Kuykendall, A.T.; Vannucchi, A.M.; et al. Phase III MANIFEST-2: Pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. *Future Oncol.* **2022**, *18*, 2987–2997. [[CrossRef](#)] [[PubMed](#)]
103. Mills, R.J.; Humphrey, S.J.; Fortuna, P.R.J.; Lor, M.; Foster, S.R.; Quaipe-Ryan, G.A.; Johnston, R.L.; Dumenil, T.; Bishop, C.; Rudraraju, R.; et al. BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. *Cell* **2021**, *184*, 2167–2182.e22. [[CrossRef](#)] [[PubMed](#)]

104. McIntyre, R.L.; Daniels, E.G.; Molenaars, M.; Houtkooper, R.H.; Janssens, G.E. From molecular promise to preclinical results: HDAC inhibitors in the race for healthy aging drugs. *EMBO Mol. Med.* **2019**, *11*, e9854. [[CrossRef](#)]
105. Gerhart-Hines, Z.; Rodgers, J.T.; Bare, O.; Lerin, C.; Kim, S.H.; Mostoslavsky, R.; Alt, F.W.; Wu, Z.; Puigserver, P. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. *EMBO J.* **2007**, *26*, 1913–1923. [[CrossRef](#)]
106. Beharry, A.W.; Sandesara, P.B.; Roberts, B.M.; Ferreira, L.F.; Senf, S.M.; Judge, A.R. HDAC1 activates FoxO and is both sufficient and required for skeletal muscle atrophy. *J. Cell Sci.* **2014**, *127*, 1441–1453. [[CrossRef](#)]
107. Fang, M.; Fan, Z.; Tian, W.; Zhao, Y.; Li, P.; Xu, H.; Zhou, B.; Zhang, L.; Wu, X.; Xu, Y. HDAC4 mediates IFN-gamma induced disruption of energy expenditure-related gene expression by repressing SIRT1 transcription in skeletal muscle cells. *Biochim. Biophys. Acta* **2016**, *1859*, 294–305. [[CrossRef](#)] [[PubMed](#)]
108. Mihaylova, M.M.; Vasquez, D.S.; Ravnskjaer, K.; Denechaud, P.D.; Yu, R.T.; Alvarez, J.G.; Downes, M.; Evans, R.M.; Montminy, M.; Shaw, R.J. Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. *Cell* **2011**, *145*, 607–621. [[CrossRef](#)] [[PubMed](#)]
109. Ratti, F.; Ramond, F.; Moncollin, V.; Simonet, T.; Milan, G.; Mejat, A.; Thomas, J.L.; Streichenberger, N.; Gilquin, B.; Matthias, P.; et al. Histone deacetylase 6 is a FoxO transcription factor-dependent effector in skeletal muscle atrophy. *J. Biol. Chem.* **2015**, *290*, 4215–4224. [[CrossRef](#)]
110. Moresi, V.; Williams, A.H.; Meadows, E.; Flynn, J.M.; Potthoff, M.J.; McAnally, J.; Shelton, J.M.; Backs, J.; Klein, W.H.; Richardson, J.A.; et al. Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases. *Cell* **2010**, *143*, 35–45. [[CrossRef](#)]
111. Moreno-Ruperez, A.; Priego, T.; Gonzalez-Nicolas, M.A.; Lopez-Calderon, A.; Lazaro, A.; Martin, A.I. Role of Glucocorticoid Signaling and HDAC4 Activation in Diaphragm and Gastrocnemius Proteolytic Activity in Septic Rats. *Int. J. Mol. Sci.* **2022**, *23*, 3641. [[CrossRef](#)]
112. Yoshihara, T.; Tsuzuki, T.; Chang, S.W.; Kakigi, R.; Sugiura, T.; Naito, H. Exercise preconditioning attenuates hind limb unloading-induced gastrocnemius muscle atrophy possibly via the HDAC4/Gadd45 axis in old rats. *Exp. Gerontol.* **2019**, *122*, 34–41. [[CrossRef](#)]
113. Du Bois, P.; Pablo Tortola, C.; Lodka, D.; Kny, M.; Schmidt, F.; Song, K.; Schmidt, S.; Bassel-Duby, R.; Olson, E.N.; Fielitz, J. Angiotensin II Induces Skeletal Muscle Atrophy by Activating TFEB-Mediated MuRF1 Expression. *Circ. Res.* **2015**, *117*, 424–436. [[CrossRef](#)]
114. Dupre-Aucouturier, S.; Castells, J.; Freyssenet, D.; Desplanches, D. Trichostatin A, a histone deacetylase inhibitor, modulates unloaded-induced skeletal muscle atrophy. *J. Appl. Physiol.* **2015**, *119*, 342–351. [[CrossRef](#)]
115. Iezzi, S.; Di Padova, M.; Serra, C.; Caretti, G.; Simone, C.; Maklan, E.; Minetti, G.; Zhao, P.; Hoffman, E.P.; Puri, P.L.; et al. Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. *Dev. Cell* **2004**, *6*, 673–684. [[CrossRef](#)]
116. Proserpio, V.; Fittipaldi, R.; Ryall, J.G.; Sartorelli, V.; Caretti, G. The methyltransferase SMYD3 mediates the recruitment of transcriptional cofactors at the myostatin and c-Met genes and regulates skeletal muscle atrophy. *Genes. Dev.* **2013**, *27*, 1299–1312. [[CrossRef](#)]
117. Nemoto, S.; Fergusson, M.M.; Finkel, T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1alpha. *J. Biol. Chem.* **2005**, *280*, 16456–16460. [[CrossRef](#)] [[PubMed](#)]
118. Gomes, A.P.; Price, N.L.; Ling, A.J.; Moslehi, J.J.; Montgomery, M.K.; Rajman, L.; White, J.P.; Teodoro, J.S.; Wrann, C.D.; Hubbard, B.P.; et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. *Cell* **2013**, *155*, 1624–1638. [[CrossRef](#)] [[PubMed](#)]
119. Dasgupta, A.; Shukla, S.K.; Vernucci, E.; King, R.J.; Abrego, J.; Mulder, S.E.; Mullen, N.J.; Graves, G.; Buettner, K.; Thakur, R.; et al. SIRT1-NOX4 signaling axis regulates cancer cachexia. *J. Exp. Med.* **2020**, *217*, e20190745. [[CrossRef](#)]
120. Phillips, T.; Leeuwenburgh, C. Muscle fiber specific apoptosis and TNF-alpha signaling in sarcopenia are attenuated by life-long calorie restriction. *FASEB J.* **2005**, *19*, 668–670. [[CrossRef](#)]
121. Tseng, Y.C.; Kulp, S.K.; Lai, I.L.; Hsu, E.C.; He, W.A.; Frankhouser, D.E.; Yan, P.S.; Mo, X.; Bloomston, M.; Lesinski, G.B.; et al. Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia. *J. Natl. Cancer Inst.* **2015**, *107*, djv274. [[CrossRef](#)] [[PubMed](#)]
122. Benny Klimek, M.E.; Aydogdu, T.; Link, M.J.; Pons, M.; Koniaris, L.G.; Zimmers, T.A. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. *Biochem. Biophys. Res. Commun.* **2010**, *391*, 1548–1554. [[CrossRef](#)] [[PubMed](#)]
123. Bonetto, A.; Penna, F.; Minero, V.G.; Reffo, P.; Bonelli, G.; Baccino, F.M.; Costelli, P. Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice. *Curr. Cancer Drug Targets* **2009**, *9*, 608–616. [[CrossRef](#)] [[PubMed](#)]
124. Sun, R.; Zhang, S.; Hu, W.; Lu, X.; Lou, N.; Yang, Z.; Chen, S.; Zhang, X.; Yang, H. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPbeta-regulated Atrogin 1 expression in cancer cachexia. *Am. J. Physiol. Cell Physiol.* **2016**, *311*, C101–C115. [[CrossRef](#)] [[PubMed](#)]
125. Walsh, M.E.; Bhattacharya, A.; Sataranatarajan, K.; Qaisar, R.; Sloane, L.; Rahman, M.M.; Kinter, M.; Van Remmen, H. The histone deacetylase inhibitor butyrate improves metabolism and reduces muscle atrophy during aging. *Aging Cell* **2015**, *14*, 957–970. [[CrossRef](#)] [[PubMed](#)]

126. Zhou, J.; So, K.K.; Li, Y.; Li, Y.; Yuan, J.; Ding, Y.; Chen, F.; Huang, Y.; Liu, J.; Lee, W.; et al. Elevated H3K27ac in aged skeletal muscle leads to increase in extracellular matrix and fibrogenic conversion of muscle satellite cells. *ging Cell* **2019**, *18*, e12996. [[CrossRef](#)] [[PubMed](#)]
127. Dai, Z.; Ramesh, V.; Locasale, J.W. The evolving metabolic landscape of chromatin biology and epigenetics. *Nat. Rev. Genet.* **2020**, *21*, 737–753. [[CrossRef](#)] [[PubMed](#)]
128. Argiles, J.M.; Busquets, S.; Stemmler, B.; Lopez-Soriano, F.J. Cachexia and sarcopenia: Mechanisms and potential targets for intervention. *Curr. Opin. Pharmacol.* **2015**, *22*, 100–106. [[CrossRef](#)]
129. Petruzzelli, M.; Wagner, E.F. Mechanisms of metabolic dysfunction in cancer-associated cachexia. *Genes. Dev.* **2016**, *30*, 489–501. [[CrossRef](#)]
130. Pietrocola, F.; Galluzzi, L.; Bravo-San Pedro, J.M.; Madeo, F.; Kroemer, G. Acetyl coenzyme A: A central metabolite and second messenger. *Cell Metab.* **2015**, *21*, 805–821. [[CrossRef](#)]
131. Beltra, M.; Pollanen, N.; Fornelli, C.; Tonttila, K.; Hsu, M.Y.; Zampieri, S.; Moletta, L.; Corra, S.; Porporato, P.E.; Kivela, R.; et al. NAD(+) repletion with niacin counteracts cancer cachexia. *Nat. Commun.* **2023**, *14*, 1849. [[CrossRef](#)]
132. Lapatto, H.A.K.; Kuusela, M.; Heikkinen, A.; Muniandy, M.; van der Kolk, B.W.; Gopalakrishnan, S.; Pollanen, N.; Sandvik, M.; Schmidt, M.S.; Heinonen, S.; et al. Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study. *Sci. dv.* **2023**, *9*, eadd5163. [[CrossRef](#)] [[PubMed](#)]
133. Mentch, S.J.; Locasale, J.W. One-carbon metabolism and epigenetics: Understanding the specificity. *nn. N. Y. cad. Sci.* **2016**, *1363*, 91–98. [[CrossRef](#)] [[PubMed](#)]
134. Luo, H.; Zhou, Y.; Liu, W. Metabolic Remodeling Impacts the Epigenetic Landscape of Dental Mesenchymal Stem Cells. *Stem Cells Int.* **2022**, *2022*, 3490433. [[CrossRef](#)] [[PubMed](#)]
135. Antoun, E.; Garratt, E.S.; Taddei, A.; Burton, M.A.; Barton, S.J.; Titcombe, P.; Westbury, L.D.; Baczynska, A.; Migliavacca, E.; Feige, J.N.; et al. Epigenome-wide association study of sarcopenia: Findings from the Hertfordshire Sarcopenia Study (HSS). *J. Cachexia Sarcopenia Muscle* **2022**, *13*, 240–253. [[CrossRef](#)]
136. Walsh, M.E.; Van Remmen, H. Emerging roles for histone deacetylases in age-related muscle atrophy. *Nutr. Healthy ging* **2016**, *4*, 17–30. [[CrossRef](#)]
137. Liva, S.G.; Tseng, Y.C.; Dauki, A.M.; Sovic, M.G.; Vu, T.; Henderson, S.E.; Kuo, Y.C.; Benedict, J.A.; Zhang, X.; Remaily, B.C.; et al. Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor. *EMBO Mol. Med.* **2020**, *12*, e9910. [[CrossRef](#)]
138. Bora, V.; Patel, D.; Johar, K.; Goyal, R.K.; Patel, B.M. Systemic study of selected histone deacetylase inhibitors in cardiac complications associated with cancer cachexia. *Can. J. Physiol. Pharmacol.* **2022**, *100*, 240–251. [[CrossRef](#)]
139. Molinari, S.; Imbriano, C.; Moresi, V.; Renzini, A.; Belluti, S.; Lozanoska-Ochser, B.; Gigli, G.; Cedola, A. Histone deacetylase functions and therapeutic implications for adult skeletal muscle metabolism. *Front. Mol. Biosci.* **2023**, *10*, 1130183. [[CrossRef](#)]
140. Judge, S.M.; Wu, C.L.; Beharry, A.W.; Roberts, B.M.; Ferreira, L.F.; Kandarian, S.C.; Judge, A.R. Genome-wide identification of FoxO-dependent gene networks in skeletal muscle during C26 cancer cachexia. *BMC Cancer* **2014**, *14*, 997. [[CrossRef](#)]
141. Yamamoto, H.; Williams, E.G.; Mouchiroud, L.; Canto, C.; Fan, W.; Downes, M.; Heligon, C.; Barish, G.D.; Desvergne, B.; Evans, R.M.; et al. NCoR1 is a conserved physiological modulator of muscle mass and oxidative function. *Cell* **2011**, *147*, 827–839. [[CrossRef](#)]
142. Lee, B.; Sahoo, A.; Marchica, J.; Holzhauser, E.; Chen, X.; Li, J.L.; Seki, T.; Govindarajan, S.S.; Markey, F.B.; Batish, M.; et al. The long noncoding RNA SPRIGHTLY acts as an intranuclear organizing hub for pre-mRNA molecules. *Sci. dv.* **2017**, *3*, e1602505. [[CrossRef](#)] [[PubMed](#)]
143. Marceca, G.P.; Nigita, G.; Calore, F.; Croce, C.M. MicroRNAs in Skeletal Muscle and Hints on Their Potential Role in Muscle Wasting During Cancer Cachexia. *Front. Oncol.* **2020**, *10*, 607196. [[CrossRef](#)] [[PubMed](#)]
144. Zhou, X.; Hu, S.; Zhang, Y.; Du, G.; Li, Y. The mechanism by which noncoding RNAs regulate muscle wasting in cancer cachexia. *Precis. Clin. Med.* **2021**, *4*, 136–147. [[CrossRef](#)]
145. Yedigaryan, L.; Gatti, M.; Marini, V.; Maraldi, T.; Sampaolesi, M. Shared and Divergent Epigenetic Mechanisms in Cachexia and Sarcopenia. *Cells* **2022**, *11*, 2293. [[CrossRef](#)] [[PubMed](#)]
146. Zhang, A.; Li, M.; Wang, B.; Klein, J.D.; Price, S.R.; Wang, X.H. miRNA-23a/27a attenuates muscle atrophy and renal fibrosis through muscle-kidney crosstalk. *J. Cachexia Sarcopenia Muscle* **2018**, *9*, 755–770. [[CrossRef](#)]
147. He, W.A.; Berardi, E.; Cardillo, V.M.; Acharyya, S.; Aulino, P.; Thomas-Ahner, J.; Wang, J.; Bloomston, M.; Muscarella, P.; Nau, P.; et al. NF-kappaB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. *J. Clin. Investig.* **2013**, *123*, 4821–4835. [[CrossRef](#)]
148. Penna, F.; Costamagna, D.; Fanzani, A.; Bonelli, G.; Baccino, F.M.; Costelli, P. Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. *PLoS ONE* **2010**, *5*, e13604. [[CrossRef](#)]
149. Garcia-Prat, L.; Martinez-Vicente, M.; Perdiguero, E.; Ortet, L.; Rodriguez-Ubreva, J.; Rebollo, E.; Ruiz-Bonilla, V.; Gutarra, S.; Ballestar, E.; Serrano, A.L.; et al. Autophagy maintains stemness by preventing senescence. *Nature* **2016**, *529*, 37–42. [[CrossRef](#)]
150. Iezzi, S.; Cossu, G.; Nervi, C.; Sartorelli, V.; Puri, P.L. Stage-specific modulation of skeletal myogenesis by inhibitors of nuclear deacetylases. *Proc. Natl. cad. Sci. US* **2002**, *99*, 7757–7762. [[CrossRef](#)]
151. Lu, J.; McKinsey, T.A.; Nicol, R.L.; Olson, E.N. Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. *Proc. Natl. cad. Sci. US* **2000**, *97*, 4070–4075. [[CrossRef](#)]

152. Miska, E.A.; Karlsson, C.; Langley, E.; Nielsen, S.J.; Pines, J.; Kouzarides, T. HDAC4 deacetylase associates with and represses the MEF2 transcription factor. *EMBO J.* **1999**, *18*, 5099–5107. [[CrossRef](#)]
153. Lu, J.; McKinsey, T.A.; Zhang, C.L.; Olson, E.N. Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. *Mol. Cell* **2000**, *6*, 233–244. [[CrossRef](#)]
154. Dressel, U.; Bailey, P.J.; Wang, S.C.; Downes, M.; Evans, R.M.; Muscat, G.E. A dynamic role for HDAC7 in MEF2-mediated muscle differentiation. *J. Biol. Chem.* **2001**, *276*, 17007–17013. [[CrossRef](#)]
155. McKinsey, T.A.; Zhang, C.L.; Lu, J.; Olson, E.N. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. *Nature* **2000**, *408*, 106–111. [[CrossRef](#)]
156. Roberts, T.C.; Etxaniz, U.; Dall’Agnese, A.; Wu, S.Y.; Chiang, C.M.; Brennan, P.E.; Wood, M.J.A.; Puri, P.L. BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis. *Sci. Rep.* **2017**, *7*, 6153. [[CrossRef](#)] [[PubMed](#)]
157. Pin, F.; Bonewald, L.F.; Bonetto, A. Role of myokines and osteokines in cancer cachexia. *Exp. Biol. Med.* **2021**, *246*, 2118–2127. [[CrossRef](#)]
158. Argilés, J.M.; Stemmler, B.; López-Soriano, F.J.; Busquets, S. Inter-tissue communication in cancer cachexia. *Nat. Rev. Endocrinol.* **2018**, *15*, 9–20. [[CrossRef](#)] [[PubMed](#)]
159. He, C.; He, W.; Hou, J.; Chen, K.; Huang, M.; Yang, M.; Luo, X.; Li, C. Bone and Muscle Crosstalk in Aging. *Front. Cell Dev. Biol.* **2020**, *8*, 585644. [[CrossRef](#)] [[PubMed](#)]
160. Li, G.; Zhang, L.; Wang, D.; AIQudsy, L.; Jiang, J.X.; Xu, H.; Shang, P. Muscle-bone crosstalk and potential therapies for sarco-osteoporosis. *J. Cell Biochem.* **2019**, *120*, 14262–14273. [[CrossRef](#)] [[PubMed](#)]
161. Wang, N.; Wang, H.; Chen, J.; Wang, F.; Wang, S.; Zhou, Q.; Ying, J.; Huang, S.; Wang, P.; Yuan, F. ACY-1215, a HDAC6 inhibitor, decreases the dexamethasone-induced suppression of osteogenesis in MC3T3-E1 cells. *Mol. Med. Rep.* **2020**, *22*, 2451–2459. [[CrossRef](#)]
162. Shakibaei, M.; Buhmann, C.; Mobasheri, A. Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kappaB ligand (RANKL) activation of NF-kappaB signaling and inhibit osteoclastogenesis in bone-derived cells. *J. Biol. Chem.* **2011**, *286*, 11492–11505. [[CrossRef](#)] [[PubMed](#)]
163. Bradley, E.W.; Carpio, L.R.; van Wijnen, A.J.; McGee-Lawrence, M.E.; Westendorf, J.J. Histone Deacetylases in Bone Development and Skeletal Disorders. *Physiol. Rev.* **2015**, *95*, 1359–1381. [[CrossRef](#)]
164. Baud’huin, M.; Lamoureux, F.; Jacques, C.; Rodriguez Calleja, L.; Quillard, T.; Charrier, C.; Amiaud, J.; Berreur, M.; Brounais-LeRoyer, B.; Owen, R.; et al. Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis. *Bone* **2017**, *94*, 10–21. [[CrossRef](#)] [[PubMed](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.